US Patent

US7951400 — Coated tablet formulation and method

Formulation · Assigned to Bristol Myers Squibb Co · Expires 2028-11-30 · 3y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a coated tablet formulation that includes saxagliptin hydrochloride, a DPP4-inhibitor, and various conventional excipients.

USPTO Abstract

A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxagliptin or its HCl salt, which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.

Drugs covered by this patent

Patent Metadata

Patent number
US7951400
Jurisdiction
US
Classification
Formulation
Expires
2028-11-30
Drug substance claim
No
Drug product claim
Yes
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.